Background And Aims: General anaesthesia (GA) is the preferred modality for breast surgeries; however, neuraxial anaesthesia can be performed in cases where GA poses a significant risk. We hypothesise that neuraxial blockade is a safe and effective alternative to GA in short-duration breast surgeries.
Methods: This randomised study included 30 patients of the American Society of Anesthesiologists physical status I and II, who were scheduled for elective breast surgeries of a duration of less than 90 min. Group I received thoracic spinal anaesthesia, while in Group II, standardised GA was administered. The primary outcome was the time to the first rescue analgesic, and the secondary outcomes were time to recovery, patient satisfaction and the cost incurred.
Results: The demographic characteristics of both groups were comparable ( > 0.05). The time to first rescue analgesic in Group I was more than in Group II ( = 0.001). Patient satisfaction score was superior in Group I compared to Group II ( = 0.002). The average cost was lower in Group I compared to Group II ( = 0.002). Recovery was quicker in Group I than in Group II ( = 0.001). There were no significant haemodynamic disturbances or major complications in either group.
Conclusion: Thoracic spinal anaesthesia is an excellent alternative to GA in terms of analgesic efficacy, patient satisfaction, recovery and cost-effectiveness for short-duration breast surgeries.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498257 | PMC |
http://dx.doi.org/10.4103/ija.ija_629_24 | DOI Listing |
J Transl Med
January 2025
Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
In contemporary times, cancer poses the most significant threat to human life and safety. Scientists have relentlessly pursued the intricacies of carcinogenesis and explored ways to prevent and treat cancer. Carcinogenesis is a complex, multi-faceted, and multi-stage process, with numerous underlying causes, including inflammation and fibrosis.
View Article and Find Full Text PDFBMC Cancer
January 2025
Oncology Unit, Surgery Department, University College Hospital, Ibadan, Nigeria.
Background: Breast cancer is the leading cause of cancer among women globally and the most common cancer among women in Sierra Leone. This study aimed to evaluate the patterns of clinical presentation, management and outcomes among breast cancer patients who presented at the Connaught Teaching Hospital Complex in Sierra Leone.
Method: A retrospective, cross-sectional study was conducted at the specialist outpatient clinic at the Connaught Hospital.
Ann Surg Oncol
January 2025
Department of Surgery, University of Rochester, Rochester, NY, USA.
Radiat Res
January 2025
Department of Molecular Biosciences, Stockholm University, Stockholm, Sweden.
The role of genetics in susceptibility to radiotherapy-induced toxicities is unclear. A strong impact of genetics should cause correlated toxicities in patients with metachronous double radiotherapy. We ascertained information about demographics, lifestyle, radiotherapy and early toxicities in irradiated tissues for a retrospective cohort of 98 patients from 2 hospitals who underwent two metachronous radiotherapeutic treatments (2007-2022) of different anatomical regions.
View Article and Find Full Text PDFTransl Oncol
January 2025
Department of Breast Surgery, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai 264003, China. Electronic address:
Background: Breast cancer had been the most frequently diagnosed cancer among women, making up nearly one-third of all female cancers. Hormone receptor-positive breast cancer (HR+BC) was the most prevalent subtype of breast cancer and exhibited significant heterogeneity. Despite advancements in endocrine therapies, patients with advanced HR+BC often faced poor outcomes due to the development of resistance to treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!